American Bio Medica Corporation (ABMC)
- Previous Close
0.0001 - Open
0.0001 - Bid --
- Ask --
- Day's Range
0.0001 - 0.0001 - 52 Week Range
0.0001 - 0.0002 - Volume
10,500 - Avg. Volume
419 - Market Cap (intraday)
4,810 - Beta (5Y Monthly) -17.09
- PE Ratio (TTM)
0.00 - EPS (TTM)
0.0200 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
American Bio Medica Corporation engages in manufacture and sale of lateral flow immunoassay tests primarily for the immediate detection of drugs in urine and oral fluids. Its drugs detection products in urine include Rapid Drug Screen, a rapid drug test, which detects the presence or absence of 2 to 10 drugs; RDS InCup, a drug-testing cup that detects the presence or absence of 1 to 12 drugs; Rapid TOX, a drug test in a cassette platform, which detects the presence or absence of 1 to 10 drugs; and Rapid TOX Cup II, a drug testing cup that detects the presence or absence of 1 to 16 drugs. The company also offers a test for the detection of respiratory syncytial virus; OralStat, a drug test for the detection of drugs in oral fluids, as well as private labeled versions of OralStat. In addition, the company distributes other products for the detection of substances of abuse, as well as products to detect certain infectious diseases. Further, it provides strip contract manufacturing, assembly, and packaging services to unaffiliated diagnostic companies. The company serves rehabilitation/drug treatment, pain management, other clinical, government, and employment/workplace markets. It operates in the United States, North America, Europe, the Asia Pacific, and South America. The company was formerly known as American Micro Media, Inc. and changed its name to American Bio Medica Corporation in September 1992. American Bio Medica Corporation was incorporated in 1986 and is based in Kinderhook, New York.
www.abmc.com16
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: ABMC
View MorePerformance Overview: ABMC
Trailing total returns as of 5/22/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ABMC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ABMC
View MoreValuation Measures
Market Cap
4.81k
Enterprise Value
111.81k
Trailing P/E
0.01
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.01
Price/Book (mrq)
--
Enterprise Value/Revenue
0.15
Enterprise Value/EBITDA
0.10
Financial Highlights
Profitability and Income Statement
Profit Margin
117.08%
Return on Assets (ttm)
-68.18%
Return on Equity (ttm)
--
Revenue (ttm)
726k
Net Income Avi to Common (ttm)
850k
Diluted EPS (ttm)
0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
68k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-830.5k